University of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (40)

2022

  1. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

    Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634

  2. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390

  3. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 9, pp. 1854-1862

  4. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

  5. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

2021

  1. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

    JNCI Cancer Spectrum, Vol. 4, Núm. 1

  2. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535

2019

  1. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study

    Journal of Clinical Oncology

2018

  1. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

    Annals of Oncology, Vol. 29, Núm. 3, pp. 669-680

  2. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126

  3. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

    Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947

  4. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

    New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763

2016

  1. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

    European Journal of Cancer, Vol. 53, pp. 75-83

  2. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials

    Journal of Clinical Oncology, Vol. 34, Núm. 29, pp. 3518-3528

  3. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

    European Journal of Cancer, Vol. 56, pp. 85-92

  4. Palbociclib and letrozole in advanced breast cancer

    New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936

2015

  1. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial

    Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728

  2. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

    European Journal of Cancer